Escient Pharmaceuticals Announces Oral Presentation of Data Highlighting the Preclinical Development of EP262 at the 6th GA2LEN Global Urticaria Forum
EP262 potently inhibits MRGPRX2-mediated mast cell degranulation in multiple in vitro assays and in vivo using a proprietary humanized MRGPRX2 knock-in model Data supports evaluation of EP262
Source: finanznachrichten.de